article thumbnail

Lilly defers Alzheimer’s drug filing after CMS’ ‘disappointing’ decision

pharmaphorum

“We’re disappointed with the position that [CMS] has taken in its draft national coverage determination decision,” said Lilly’s chief scientific and medical officer Dan Skovronsky on the call, adding that it “essentially negates” the intention of providing patient benefit in areas of unmet medical need.

article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2023 Medicare Updates – What You Need to Know

Community Pharmacy

If this applies to you, then you can begin your application process here to get the process started. Medicare Part D has four phases of coverage that users need to be aware of before and during enrollment in the program. In 2022, the initial coverage limit was $4,430. In 2022, the coverage gap limit was $7,050.

article thumbnail

Express Scripts on the Road to Damascus?

Ramblings of a pharmacist

Separately, I don’t believe that 90-day supplies actually drive true adherence or clinical improvement - they just move the process measure of PDC. They aren’t connected to a mother caring for a kid with strep throat and ailing parents with uncontrolled diabetes. Make cost number go down, make profit number go up.

article thumbnail

NHC’s comments in response to the 2025 Notice of Benefit and Payment Parameters (NBPP)

Putting Patients First Blog

Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.

article thumbnail

Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol

pharmaphorum

Open protocol, simply put, is a digital language that facilitates electronic transactions among prescribers, pharmacies, patient support vendors, data aggregators, insurers, and other stakeholders in the specialty pharmaceutical patient journey. The patient’s journey is typically long and complicated ? About the author.

HIPAA 98
article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

More than 30 million Americans have diabetes and another 88 million are at risk of developing it. Pharmacists have more insight into a patient’s insurance coverage than most providers, so this change could create a lot of value for patients throughout the country. One of these markets is the insulin market.